R S Herbst

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Therapeutic options to target angiogenesis in human malignancies
    Roy S Herbst
    University of Texas M D Anderson Cancer Center, Department of Thoracic Head and Neck Medical Oncology, Houston, TX 77030 4009, USA
    Expert Opin Emerg Drugs 11:635-50. 2006
  2. pmc Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, Section of Thoracic Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 28:4747-54. 2010
  3. pmc Role of novel targeted therapies in the clinic
    R S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 432, Houston, TX 77030 4009, USA
    Br J Cancer 92:S21-7. 2005
  4. ncbi request reprint Angiogenesis and lung cancer: prognostic and therapeutic implications
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030 4009, USA
    J Clin Oncol 23:3243-56. 2005
  5. doi request reprint Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC
    Roy S Herbst
    The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 13:1166-76. 2008
  6. ncbi request reprint Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lung Cancer 6:S7-S19. 2004
  7. ncbi request reprint Gefitinib--a novel targeted approach to treating cancer
    Roy S Herbst
    Roy S Herbst is at the Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 432, Houston, Texas 77030, USA
    Nat Rev Cancer 4:956-65. 2004
  8. ncbi request reprint Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer
    Roy S Herbst
    M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 10:4245s-4248s. 2004
  9. ncbi request reprint Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?
    Roy S Herbst
    M D Anderson Cancer Center, Department of Head and Neck Medical Oncology, Houston, Texas 77030, USA
    Oncologist 9:19-26. 2004
  10. ncbi request reprint Review of epidermal growth factor receptor biology
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Int J Radiat Oncol Biol Phys 59:21-6. 2004

Detail Information

Publications104 found, 100 shown here

  1. ncbi request reprint Therapeutic options to target angiogenesis in human malignancies
    Roy S Herbst
    University of Texas M D Anderson Cancer Center, Department of Thoracic Head and Neck Medical Oncology, Houston, TX 77030 4009, USA
    Expert Opin Emerg Drugs 11:635-50. 2006
    ..This review summarises the current literature on the use of these agents to interfere with VEGF, VEGF receptor, the matrix breakdown or other mechanisms involved in angiogenesis...
  2. pmc Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, Section of Thoracic Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 28:4747-54. 2010
    ..This randomized phase II trial was designed to select a cetuximab plus chemotherapy regimen for phase III evaluation...
  3. pmc Role of novel targeted therapies in the clinic
    R S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 432, Houston, TX 77030 4009, USA
    Br J Cancer 92:S21-7. 2005
    ....
  4. ncbi request reprint Angiogenesis and lung cancer: prognostic and therapeutic implications
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030 4009, USA
    J Clin Oncol 23:3243-56. 2005
    ....
  5. doi request reprint Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC
    Roy S Herbst
    The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 13:1166-76. 2008
    ..In addition, the application of such personalized therapy will also depend on the availability of validated screening methods...
  6. ncbi request reprint Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lung Cancer 6:S7-S19. 2004
    ..Therefore, although more work is required, data indicate that HER1/EGFR inhibitors will play an important role in treating patients with NSCLC...
  7. ncbi request reprint Gefitinib--a novel targeted approach to treating cancer
    Roy S Herbst
    Roy S Herbst is at the Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 432, Houston, Texas 77030, USA
    Nat Rev Cancer 4:956-65. 2004
    ..Investigation of gefitinib has not only increased our knowledge about the biology of EGFR signalling, but is contributing to our evolving understanding of which tumours are EGFR dependent...
  8. ncbi request reprint Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer
    Roy S Herbst
    M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 10:4245s-4248s. 2004
    ..Enhancement of the efficacy of anticancer treatments with oblimersen bcl-2 antisense therapy represents a promising new apoptosis-modulating strategy...
  9. ncbi request reprint Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?
    Roy S Herbst
    M D Anderson Cancer Center, Department of Head and Neck Medical Oncology, Houston, Texas 77030, USA
    Oncologist 9:19-26. 2004
    ..Further work is needed to identify the best way to use bevacizumab in NSCLC, including use in combination with other biologic agents and in the adjuvant setting...
  10. ncbi request reprint Review of epidermal growth factor receptor biology
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Int J Radiat Oncol Biol Phys 59:21-6. 2004
    ..When used in combination with cytotoxic treatments, chemotherapy, and radiation, EGFR inhibitors have been able to potentiate their anticancer activity...
  11. ncbi request reprint Targeting the epidermal growth factor receptor in non-small cell lung cancer
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:5813-24. 2003
    ..We also review clinical trials with EGFR-TK inhibitors in NSCLC and future directions of investigation with these targeted agents...
  12. ncbi request reprint Angiogenesis pathway inhibitors
    Roy S Herbst
    Department of Cancer Biology, Radiation, University of Texas, MD Anderson Cancer Center, Houston, TX 70030 4009, USA
    Cancer Chemother Biol Response Modif 22:225-45. 2005
  13. ncbi request reprint Gefitinib: current and future status in cancer therapy
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Adv Hematol Oncol 1:466-72. 2003
    ..This article provides a detailed overview of gefitinib, the rationale for its use in a wide range of tumor types, and the current clinical development status of this novel agent...
  14. pmc Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 432, Houston, TX 77030 4009, USA
    Lancet Oncol 11:619-26. 2010
    ..These results supported investigation of the combination in this larger, definitive phase 3 trial (ZODIAC)...
  15. ncbi request reprint Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer
    Roy S Herbst
    University of Texas M D Anderson Cancer Center, Thoracic Head and Neck Medicine Clinic, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
    J Clin Oncol 28:2839-46. 2010
    ..To the best of our knowledge, this is the first in-human clinical trial to assess the safety, tolerability, pharmacokinetics, and antitumor activity of multiple intravenous doses of rhApo2L/TRAIL in patients with advanced cancer...
  16. ncbi request reprint EGFR inhibition in NSCLC: the emerging role of cetuximab
    Roy S Herbst
    Section of Thoracic Medical Oncology, Department of Thoraci Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    J Natl Compr Canc Netw 2:S41-51. 2004
    ..Results to date suggest a potential role of epidermal growth factor receptor inhibition in non-small cell lung cancer, and investigation into the optimal use of these inhibitors continues...
  17. doi request reprint Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy
    Roy S Herbst
    Section of Thoracic Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Clin Lung Cancer 10:20-7. 2009
    ....
  18. ncbi request reprint Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer
    Roy S Herbst
    The M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:4743-50. 2007
    ..A single-arm phase I and II study of bevacizumab plus erlotinib demonstrated encouraging efficacy, with a favorable safety profile...
  19. ncbi request reprint Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer
    Roy S Herbst
    M D Anderson Cancer Center, Houston, University of Texas, Houston, TX 77030 4009, USA
    Clin Cancer Res 13:s4641-6. 2007
    ..Based on the combined information, we present the rationale for its future assessment in the treatment of lung cancer...
  20. doi request reprint A first-in-human study of conatumumab in adult patients with advanced solid tumors
    Roy S Herbst
    Head and Neck Head and Neck Medical Oncology and Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:5883-91. 2010
    ..To determine the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of conatumumab, an investigational, fully human monoclonal agonist antibody against human death receptor 5, in patients with advanced solid tumors...
  21. ncbi request reprint Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis
    Roy S Herbst
    The University of Texas MD Anderson Cancer Center, Department of Thoracic Head and Neck Medical Oncology, 1515 Holcombe Boulevard, Unit 432, Houston, TX 77030 4009, USA
    Expert Opin Investig Drugs 16:239-49. 2007
    ..Clinical development is also ongoing in other tumor types and encouraging evidence of antitumor activity has been reported in patients with metastatic hereditary medullary thyroid cancer...
  22. ncbi request reprint Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:4440-7. 2002
    ..TNP-470 was administered with paclitaxel to adults with solid tumors to define the safety and optimal dose of the combination regimen and to assess pharmacokinetic interactions...
  23. ncbi request reprint Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 94:1593-611. 2002
    ..Blockade of the epidermal growth factor receptor (EGFR) and its ligands is a novel approach to the treatment of human tumors that offers a noncytotoxic alternative to cancer treatment...
  24. ncbi request reprint IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer
    R S Herbst
    Department of Thoracic and Head and Neck Medical Oncology, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Expert Opin Biol Ther 1:719-32. 2001
    ..IMC-C225 displays dose-dependent elimination characteristics and a half-life of approximately 7 days. Current recommendations for dosing include a 400 mg/m2 loading dose, followed by weekly infusions of 250 mg/m2...
  25. ncbi request reprint Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin
    Roy S Herbst
    Department of Thoracic and Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 20:3804-14. 2002
    ..We present the initial results of a dose-finding clinical trial of recombinant human endostatin (rh-Endo) that examined potential surrogates for response to antiangiogenic therapy...
  26. ncbi request reprint Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin
    R S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Box 80, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Curr Oncol Rep 3:131-40. 2001
    ..This article defines the general principles of anti-angiogenic drug action and explains how these principles have been used to design a phase I trial of human endostatin...
  27. ncbi request reprint The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 95:340-53. 2002
    ..The authors conducted a formal Phase II trial to evaluate the efficacy of this combination in both untreated and previously treated patients with Stage IIIB (with pleural effusion) or Stage IV NSCLC...
  28. ncbi request reprint Angiogenesis as a target for cancer therapy
    Kerim Kaban
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Hematol Oncol Clin North Am 16:1125-71. 2002
    ..Still, there is much to learn about the machinery that tumors use to recruit new blood vessels, and the results of the clinical trials will show the best way to apply that knowledge for cancer therapy...
  29. ncbi request reprint Phase I study of recombinant human endostatin in patients with advanced solid tumors
    Roy S Herbst
    Department of Thoracic and Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:3792-803. 2002
    ..We evaluated recombinant human endostatin (rh-Endo) in a phase I trial designed to assess safety, pharmacokinetics, and serum markers of angiogenesis in patients with solid tumors...
  30. ncbi request reprint Toxicities of antiangiogenic therapy in non-small-cell lung cancer
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lung Cancer 8:S23-30. 2006
    ..Additionally, further investigation is necessary to determine risk factors for hemorrhage with antiangiogenic agents...
  31. pmc Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer
    Keiko Shibuya
    Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 69:1534-43. 2007
    ....
  32. ncbi request reprint A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology and Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 9:4108-15. 2003
    ....
  33. ncbi request reprint TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
    Roy S Herbst
    University of Texas M D Anderson Cancer Center, Houston, USA
    J Clin Oncol 23:5892-9. 2005
    ..Erlotinib was combined with chemotherapy to determine if it could improve the outcome of patients with NSCLC...
  34. ncbi request reprint Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer
    Amir Onn
    Department of Thoracic, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 10:136-43. 2004
    ....
  35. ncbi request reprint Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 20:3815-25. 2002
    ....
  36. ncbi request reprint Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Unit 432, PO Box 301402, Houston, TX 77230 1402, USA
    J Clin Oncol 23:5578-87. 2005
    ....
  37. ncbi request reprint Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome
    Amir Onn
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 57, Houston, TX 77030, USA
    Radiology 237:342-7. 2005
    ..To retrospectively identify radiographic characteristics of stage I non-small cell lung cancer (NSCLC) that may correlate with epidermal growth factor receptor (EGFR) or HER2 expression or with prognosis...
  38. ncbi request reprint Current management of advanced non-small cell lung cancer: targeted therapy
    Takeshi Isobe
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 32:315-28. 2005
    ..Achievement of these goals will hopefully lead to incorporation of biological therapy into the current anticancer arsenal, for the benefit of lung cancer patients...
  39. ncbi request reprint Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors
    Darren W Davis
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 10:33-42. 2004
    ..The results, including tumor blood flow measured by positron emission tomography, were analyzed using a quadratic polynomial model...
  40. ncbi request reprint Angiogenesis inhibitors in clinical development for lung cancer
    Roy S Herbst
    University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Semin Oncol 29:66-77. 2002
    ..These include the potential requirement for long-term administration, difficulties in deriving biologically efficacious doses in early clinical trials, and the inability to use tumor regression as a primary endpoint in phase II trials...
  41. ncbi request reprint Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Semin Oncol 29:27-36. 2002
    ....
  42. ncbi request reprint Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy
    William N William
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Am J Clin Oncol 33:148-52. 2010
    ..The aim of this phase 2 study was to investigate the use of docetaxel and vinorelbine in the frontline and second-line setting in patients with incurable non-small-cell lung cancer...
  43. ncbi request reprint KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
    Erminia Massarelli
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 13:2890-6. 2007
    ..In contrast, KRAS mutation has been shown to predict poor response to such therapy. We tested the utility of combinations of these three markers in predicting response and survival in patients with NSCLC treated with EGFR-TKIs...
  44. doi request reprint Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer
    Emer O Hanrahan
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 15:3600-9. 2009
    ..In study 7, vandetanib monotherapy was inferior to carboplatin-paclitaxel. We performed an exploratory retrospective analysis of the relationship between baseline circulating VEGF concentrations and PFS...
  45. ncbi request reprint Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade
    Wenjuan Wu
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Unit 97, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 6:471-83. 2007
    ....
  46. ncbi request reprint [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer
    Ryohei Sasaki
    Department of Radiation Oncology, Unit 97, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 23:1136-43. 2005
    ..To determine whether the standardized uptake value (SUV) of [(18)F]fluorodeoxyglucose uptake by positron emission tomography could be a prognostic factor for non-small-cell lung cancer (NSCLC)...
  47. ncbi request reprint Mode of action of docetaxel - a basis for combination with novel anticancer agents
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology and Cancer Biology, The University of Texas, Houston, TX, USA
    Cancer Treat Rev 29:407-15. 2003
    ..How these strategies can be targeted towards specific patient populations (e.g., HER-2 overexpressing metastatic breast cancer patients) to provide optimal therapy is highlighted...
  48. ncbi request reprint A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer
    E S Kim
    Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030-4009, USA
    Lung Cancer 34:427-32. 2001
    ..The lack of encouraging results from SPI-77 use in other phase I and II studies resulted in early closure of this trial by the manufacturer...
  49. ncbi request reprint Epidermal growth factor receptor biology (IMC-C225)
    E S Kim
    Department of Thoracic Head and Neck Medical Oncology, University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    Curr Opin Oncol 13:506-13. 2001
    ..Ultimately, IMC-C225 may prove to become a valuable contributor in the treatment of cancer. This report will focus on IMC-C225, a novel monoclonal antibody that targets the EGFR...
  50. ncbi request reprint A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer
    E Massarelli
    MD Anderson Cancer Center, Thoracic Head and Neck Medical Oncology, 1515 Holcombe Boulevard, P O Box 432, Houston, TX 77030, USA
    Lung Cancer 39:55-61. 2003
    ..02). This review highlights the need for novel therapy approaches for patients with recurrent NSCLC who have failed second-line therapy and provides a baseline for the statistical design of such studies...
  51. ncbi request reprint Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung canc
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, Biostatistics and Diagnostic Radiology, The University of Texas, M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 23:2544-55. 2005
    ..Preclinical data in various xenograft models produced greater growth inhibition than with either agent alone. Additionally, both agents have demonstrated benefit in patients with previously treated non-small-cell lung cancer (NSCLC)...
  52. pmc Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice
    Satoshi Itasaka
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 67:870-8. 2007
    ....
  53. ncbi request reprint Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer
    Roy S Herbst
    The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 13:6175-81. 2007
    ..Based on supporting preclinical studies, we undertook a Phase II trial of pertuzumab in patients with recurrent non-small cell lung cancer (NSCLC)...
  54. ncbi request reprint Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer
    Amir Onn
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:8613-9. 2004
    ..The purpose is to evaluate whether inhibition of epidermal growth factor receptor (EGFR) activation by PKI166, an EGFR-tyrosine kinase inhibitor, affects growth of human lung cancer implanted orthotopically into the lungs of nude mice...
  55. ncbi request reprint Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck
    J E Tseng
    Department of Thoracic and Head and Neck Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 92:2364-73. 2001
    ..Potentially, future evaluations of thalidomide may be performed in combination with other antiangiogenic or cytotoxic agents in patients with earlier stage disease or in patients with minimal residual disease...
  56. pmc Surrogate markers in antiangiogenesis clinical trials
    D W Davis
    1Department of Cancer Biology, Unit 173, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Br J Cancer 89:8-14. 2003
    ..This review summarises the currently available clinical data on the development of surrogate markers of angiogenesis inhibitors...
  57. ncbi request reprint Emerging therapies in non-small-cell lung cancer
    F R Khuri
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Ann Oncol 12:739-44. 2001
    ....
  58. ncbi request reprint Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 30:30-8. 2003
    ....
  59. doi request reprint Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer
    Edith M Marom
    Department of Diagnostic Imaging, University of Texas, M D Anderson Cancer Center, Sheba Medical Center, Tel Hashomer, Israel
    J Thorac Oncol 3:351-7. 2008
    ....
  60. ncbi request reprint Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer
    Yun Oh
    Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 26:1135-41. 2008
    ..This phase II trial of enzastaurin was conducted to determine the 6-month progression-free survival (PFS) rate in advanced, metastatic NSCLC...
  61. ncbi request reprint Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial
    Rebecca D Pentz
    University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 20:3785-91. 2002
    ..To describe prospective participants' initial source of information about, understanding of, and motivation to participate in a phase I clinical trial of the antiangiogenesis agent human recombinant endostatin...
  62. ncbi request reprint Erlotinib (Tarceva): an update on the clinical trial program
    Roy S Herbst
    The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
    Semin Oncol 30:34-46. 2003
    ....
  63. pmc Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice
    Jörg J Jacoby
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
    J Thorac Oncol 5:940-9. 2010
    ..To determine the effectiveness of PX-478 against lung tumors, we investigated HIF-1alpha expression in several lung cancer cell lines, both in vitro and in vivo, and treated orthotopic mouse models of human lung cancer with PX-478...
  64. ncbi request reprint Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice
    Amir Onn
    Department of Thoracic Head and Neck Medical Oncology, Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:5532-9. 2003
    ..This study was conducted to develop biologically relevant animal models of human lung cancer that are reproducible, inexpensive, and easy to perform...
  65. ncbi request reprint Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice
    Wenjuan Wu
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 432, Houston, TX 77030, USA
    Mol Cancer Ther 6:2652-63. 2007
    ..Our findings provide an additional explanation for the susceptibility of lung cancers to treatment with EGFR tyrosine kinase inhibitors...
  66. ncbi request reprint Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program
    Sheeba K Thomas
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lung Cancer 7:326-31. 2006
    ..The primary objective of this retrospective study was to investigate the potential role of East Asian ethnicity or origin in predicting response to gefitinib in advanced-stage non-small-cell lung cancer (NSCLC)...
  67. ncbi request reprint Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone
    Eugene H Huang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 68:779-85. 2007
    ..To retrospectively compare outcomes for patients with unresectable locally advanced non-small-cell lung cancer (NSCLC) treated at our institution with concurrent chemoradiation with or without induction chemotherapy...
  68. ncbi request reprint IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 29:18-30. 2002
    ..IMC-C225 displays dose-dependent elimination characteristics and a half-life of approximately 7 days. Current recommendations for dosing include a 400 mg/m(2) loading dose, followed by weekly infusions at 250 mg/m(2)...
  69. doi request reprint Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)
    Hai T Tran
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 432, Houston, TX 77030, USA
    Invest New Drugs 29:499-505. 2011
    ..To assess the pharmacokinetics and evaluate potential drug-drug interactions between erlotinib, paclitaxel and carboplatin...
  70. ncbi request reprint New targets for the treatment of advanced non-small cell lung cancer
    Erminia Massarelli
    Department of Thoracic Head and Neck Medical Oncology, University of Texas, M D Anderson Cancer Center, P O Box 432, Houston, TX 77030, USA
    Cancer Chemother Biol Response Modif 20:717-61. 2002
  71. ncbi request reprint Novel therapeutics for head and neck cancer
    Edward S Kim
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Curr Opin Oncol 14:334-42. 2002
    ..Continued development of these novel agents may help improve the overall response and survival rate of patients with head and neck cancer...
  72. ncbi request reprint Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing d
    Ralph G Zinner
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Lung Cancer 44:99-110. 2004
    ....
  73. ncbi request reprint Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results
    Ralph G Zinner
    Department of Thoracic Head and Neck Medical Oncology, Division of Medicine, The University of Texas M D Anderson Cancer Center, 1515 M D Anderson Boulevard, Houston, TX 77030, USA
    Lung Cancer 37:17-27. 2002
    ..Taken together, these data indicate that trastuzumab warrants further investigation in a clinical study in selected patients with NSCLC...
  74. ncbi request reprint Molecular targeted therapy for lung cancer
    Amir Onn
    Pulmonary Medicine and Cancer Biology, MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet 366:1507-8. 2005
  75. ncbi request reprint Antiangiogenic tumor therapy
    Darren W Davis
    Department of Cancer Biology, Box 173, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Biotechniques 34:1048-50, 1052, 1054 passim. 2003
  76. ncbi request reprint Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial
    Ritsuko Komaki
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 58:1369-77. 2004
    ..To determine the ability of amifostine to reduce the severity and/or incidence of the acute toxicities of concurrent chemotherapy and radiotherapy (RT) for non-small-cell lung cancer...
  77. doi request reprint Tumor blood flow measured by perfusion computed tomography and 15O-labeled water positron emission tomography: a comparison study
    Chaan S Ng
    Department of Radiology, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Comput Assist Tomogr 33:460-5. 2009
    ..To compare blood flow measurements of tumors assessed by perfusion computed tomography (pCT) and the clinical gold standard of 15O-labeled water positron emission tomography (15O-PET)...
  78. pmc Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial
    Charles Lu
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030 4009, USA
    J Natl Cancer Inst 102:859-65. 2010
    ..CONCLUSIONS The addition of AE-941 to chemoradiotherapy did not improve overall survival in patients with unresectable stage III NSCLC. This study does not support the use of shark cartilage-derived products as therapy for lung cancer...
  79. ncbi request reprint Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer
    Ralph G Zinner
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:2449-56. 2005
    ..The primary objectives of this study were to determine the efficacy and tolerability of a pemetrexed-carboplatin combination as first-line therapy in patients with advanced nonsmall cell lung cancer...
  80. ncbi request reprint Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin
    Dominic Fan
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Mol Cancer Ther 1:595-600. 2002
    ..Our data indicate that mesothelin-producing squamous cell carcinoma of the lung may be a good target for this immunotoxin...
  81. ncbi request reprint ZD1839 (Iressa) in non-small cell lung cancer
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 7:9-15. 2002
    ..This review summarizes the currently available clinical data on the use of ZD1839 in the treatment of NSCLC...
  82. ncbi request reprint ZD1839: targeting the epidermal growth factor receptor in cancer therapy
    Roy S Herbst
    Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 432, Houston, TX 77030, USA
    Expert Opin Investig Drugs 11:837-49. 2002
    ..e., head and neck, prostate, colon and breast) and other combinations. This article provides an overview of the current profile of ZD1839...
  83. ncbi request reprint Pemetrexed in the treatment of advanced non-small-cell lung cancer: a review of the clinical data
    Ralph G Zinner
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Lung Cancer 5:S67-74. 2004
    ..Pemetrexed is clearly a useful agent in the treatment of thoracic malignancies, and is worthy of further study in combination with other drugs having novel mechanisms of action...
  84. ncbi request reprint Targeted therapy in non-small-cell lung cancer
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Oncology (Williston Park) 16:19-24. 2002
    ..It is even possible that these new biologic therapies will be used together as rational combinations (based on pathologic diagnosis) for advanced non-small-cell lung cancer...
  85. ncbi request reprint Angiogenesis inhibitors in lung cancer
    Edward S Kim
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 432, Houston 77030, USA
    Curr Oncol Rep 4:325-33. 2002
    ..It is anticipated that these new targeted therapies will play an important role, along with cytotoxic and radiation therapies, in the management of metastatic disease...
  86. ncbi request reprint Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
    J Clin Oncol 22:785-94. 2004
    ..This phase III, randomized, placebo-controlled, double-blind trial evaluated gefitinib plus paclitaxel and carboplatin in chemotherapy-naive patients with advanced NSCLC...
  87. doi request reprint A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer
    Edward S Kim
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:1713-22. 2009
    ..Cetuximab in combination with docetaxel was examined in chemotherapy-refractory/resistant patients with advanced nonsmall-cell lung cancer (NSCLC) to determine response rate, survival, safety, and pharmacokinetics (PK)...
  88. ncbi request reprint Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors
    Hai T Tran
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 54:308-14. 2004
    ..The present study was designed to determine the toxicity and pharmacokinetics of carboplatin in combination with TNP-470 in comparison with the doublet regimen of paclitaxel and carboplatin in patients with solid tumors...
  89. ncbi request reprint Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
    David A Eberhard
    Department of Pathology, Genentech Inc, San Francisco, CA, USA
    J Clin Oncol 23:5900-9. 2005
    ..KRAS is frequently activated in NSCLC. The relationship of KRAS mutations to outcome after EGFR inhibitor treatment has not been described...
  90. ncbi request reprint Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials
    Daphne W Bell
    Massachusetts General Hospital Cancer Center and Department of Pathology, Harvard Medical School, Charlestown, MA 02129, USA
    J Clin Oncol 23:8081-92. 2005
    ..The goal of this study was to determine the contribution of molecular alterations in EGFR to response and survival within the phase II (IDEAL) and phase III (INTACT) trials of gefitinib...
  91. ncbi request reprint Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
    David H Johnson
    Division of Hematology and Oncology, Vanderbilt University Medical School, 777 Preston Research Bldg, Nashville, TN, USA
    J Clin Oncol 22:2184-91. 2004
    ..To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer...
  92. ncbi request reprint Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study
    Lori J Wirth
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 9:1698-704. 2003
    ..To determine the maximum-tolerated dose of docetaxel (DOC) in combination with carboplatin (CAR) and thoracic radiotherapy (RT), in the setting of trimodality treatment of patients with stage III non-small cell lung cancer (NSCLC)...
  93. ncbi request reprint Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1
    Giuseppe Giaccone
    Vrije Universiteit Medical Center, Department of Oncology, De Boelelaan 1117, 1081 Amsterdam, The Netherlands
    J Clin Oncol 22:777-84. 2004
    ..Gefitinib has demonstrated encouraging efficacy in advanced NSCLC in phase II trials in pretreated patients, and a phase I trial of gefitinib in combination with gemcitabine and cisplatin showed favorable tolerability...
  94. ncbi request reprint Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer
    Francisco Robert
    University of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham, AL 35294 3300, USA
    J Clin Oncol 23:9089-96. 2005
    ..Secondary objectives were to gather preliminary evidence of efficacy including tumor response rate, time to progression, and overall survival...
  95. ncbi request reprint Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer
    John V Heymach
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 25:4270-7. 2007
    ..The activity of vandetanib plus docetaxel was assessed in patients with previously treated non-small-cell lung cancer (NSCLC)...
  96. ncbi request reprint In vitro and in vivo assays for the proliferative and vascular permeabilization activities of vascular endothelial growth factor (VEGF) and its receptor
    Seiji Yano
    Third Department of Internal Medicine, University of Tokushima School of Medicine, Tokushima, Japan
    Methods Mol Med 74:391-8. 2003
  97. doi request reprint Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib
    Vincent A Miller
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Howard Building, Room 1012, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 26:1472-8. 2008
    ..We conducted this phase II trial to determine the efficacy of erlotinib in patients with bronchioloalveolar carcinoma (BAC) and adenocarcinoma, BAC subtype, and to determine molecular characteristics associated with response...
  98. ncbi request reprint Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer
    Michael A Carducci
    Division of Medical Oncology, Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Clin Oncol 24:4092-9. 2006
    ..Secondary objectives were maximum-tolerated dose (MTD), pharmacokinetics (PK), toxicity, and response...
  99. pmc Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer
    Lawrence H Einhorn
    Indiana Cancer Pavilion, Indianapolis, Indiana, USA
    J Thorac Oncol 3:545-55. 2008
  100. ncbi request reprint Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies
    Jan B Vermorken
    Department of Medical Oncology, University Hospital Antwerp, Edegem, Belgium
    Cancer 112:2710-9. 2008
    ..The activity of cetuximab was compared with that of commonly used treatments in this setting...
  101. pmc Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy
    Fred R Hirsch
    Southwest Oncology Group, San Antonio, USA
    J Clin Oncol 26:3351-7. 2008
    ..Here, we evaluate EGFR FISH as a predictive marker in NSCLC patients receiving the EGFR monoclonal antibody inhibitor cetuximab plus chemotherapy...